price close busi juli
biotech discov
invent manufactur commerci medicin
treat seriou diseas
expect in-lin eylea rev inventori gross/net key lack guid remain issu
expect us ex-u eylea revenu in-lin consensu
estim base continu growth diabet retinopathi segment potenti
inventori drawdown increas discount rebat consensu estim
vs estim us vs estim ex-
us sale continu view regn decis longer provid eylea guidanc
puzzl especi sinc drug still grow yoy investor may continu
suspect lack guidanc due concern regard competitor drug
wet dme space slow us market expans challeng
face regard eylea us contract strategi believ view
unsupport growth see outsid us eylea
give guidanc set price dupix kevzara decis
partner sanofi
dupix asthma approv octob boost growth upsid await
adolesc pediatr approv
dupix expans adult asthma adolesc atop
dermat earli acceler growth pediatr approv
atop dermat mo year may occur asthma move
dupix growth higher least among allergist adopt faster vs
pulmonologist uptak slower importantli expect off-label use
among pediatr atop dermat due sensit treat children
initi phase studi younger pediatr sever atop dermat patient
month year old close monitor better determin like launch
pipelin specif cemiplimab cancer like key focu earn call
expect focu cemiplimab develop lung cancer major
growth driver go forward competit market look key
might differenti develop program given merck keytruda bristol
nivolumab alreadi approv lung cancer albeit keytruda front-lin
label also look addit detail wholli own asset earlier
pipelin believ investor continu look move away share
asset sanofi toward fulli own asset garner major
econom
maintain hold pt base continu concern lack eylea guidanc
potenti competit roch dme novarti brolucizumab
wet late believ dupix like approv
uncontrol persist asthma octob view pediatr indic approv
key impact inflect point compani cemiplimab approv
cscc highli like octob also continu monitor develop
frontlin nsclc trial high bar success incumb therapi
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
expect in-lin us eylea
expect us ex-u eylea number in-lin estim well
consensu import detail come inventori level us
discounts/reb earn call manag mention
eylea distributor inventori experienc modest increas compar fourth
quarter yet remain within normal one two-week target rang
estim sales/day thu day
inventori increas inventori draw would decreas us eylea
sale averag reduc us eylea estim
time discount rebat eylea increas look
inform call whether trend persist suspect
roch continu use discount lucenti tri compet eylea
view eylea superior product
figur eylea us ex-u sale actual vs canaccord genuiti estim vs consensu
us dupix expect show steadi growth sanofi may provid detail
expect us dupix revenu beat/miss indic base
estim consensu base steadi uptak adult atop
dermat market sanofi report juli edt
give us ex-u dupix revenu number well like provid color
call would suspect much off-label use asthma time base
prescript data listen detail sanofi regeneron
inventori level key assess true demand growth
base us prescript data rais dupix estim
consensu expect consist
growth rate dupix anticip inflect us asthma approv
late octob
figur dupix us ex-u sale actual vs canaccord genuiti estim vs consensu
eylea still guidanc despit strong us
eylea constitut total revenu nearli product
revenu base report sale thu us eylea sale guidanc essenti
import product sale guidanc provid howev
decis made stop give guidanc one-year lead time
give spend guidanc tax rate
eylea continu show strong growth us growth vs
growth vs howev worri investor view
lack us eylea guidanc sign concern competit
roch novarti wet slow us market growth
difficulti contract strategi us
overal revenu guidanc would use investor gaug perform
compani sanofi collabor financi complex account
standpoint therefor could give guidanc overal sanofi collabor
may challeng investor interpret long investor
know us ex-u report sale product sanofi collabor revenu could
still use guidanc point
importantli give guidanc key asset dupix praluent
kevzara zaltrap cemiplimab sanofi partner program sinc sanofi
book global net product sale also control price
asset effect limit insight potenti perform
revenu sourc outsid eylea investor make lack eylea
competit concern data sacrif efficaci less frequent dose
believ novarti roch tri fit drug extend
dose schedul rather determin dose interv give best
efficaci doctor real world therefor concern
potenti competit believ eylea strong efficaci safeti profil
head head studi wet agent high competit barrier
eylea like expand maximum potenti us wet market
remain growth diabet macular edema diabet relat diseas
segment slower steadi challeng area investor
gain insight like us contract discount area may
concern competit market expans sinc avastin low price
curtail abil rais eylea process time cushion growth
dupix asthma boost growth
anticip posit respons fda octob dupix
use uncontrol moderate-to-sever persist asthma patient year old
expect support dupix growth await uptak trend
asthma sinc pulmonologist treat major asthma patient current
prescrib mani inject drug
pulmonologist uptak key xolair use suggest major prescrib
manag indic dupix asthma formul
pre-fil autoinjector pen like prescrib either allergist
pulmonologist given uncontrol moderate-to-sever persist asthma
patient like impact lung function pulmonologist like
domin prescrib pen formul would conveni patient
pulmonologist administ howev sinc pulmonologist less familiar
inject drug believ uptak dupix would slower moder
result still maintain posit outlook asthma indic
consider growth driver sinc dupix shown provid good
asthma exacerb control quest ventur trial
believ prescrib distribut novarti xolair repres
initi prescrib dupix importantli recent studi base us medic
pharmaci claim data show patient receiv xolair treat
allergist immunologist figur link poster interestingli recent studi
also indic low percentag patient util long-cours oral
corticosteroid high percentag util short-cours oral corticosteroid
rescu use may suggest doctor reluct add glucocorticosteroid
inhal therapi provid interest commerci opportun dupix
figur baselin characterist asthma patient newli treat omalizumab us
figur baselin asthma-rel medic usag among asthma patient newli treat
phase dupix asthma data support notabl reduct exacerb
dupix show statist signific reduct sever asthma exacerb
phase liberti asthma quest trial trial report adjust annual
rate sever asthma exacerb arm vs placebo
translat lower rate asthma exacerb
arm rate vs placebo lower rate
asthma exacerb chang bronchodil week
dupix vs placebo improv
arm vs placebo
liberti asthma quest trial patient year old
uncontrol asthma medium-to-high-dos inhal glucocorticoid
given add-on subcutan dupix dose mg everi week
matched-volum placebo week patient assess
annual rate sever asthma exacerb absolut chang forc
expiratori volum second bronchodil use week sever
asthma exacerb defin deterior asthma lead day
system glucocorticoid treatment hospit emerg visit lead
figur summari primari secondari efficaci endpoint phase liberti studi dupix asthma
demonstr dupix provid strong asthma exacerb
control patient advanc asthma diseas specif receiv
system glucocorticoid treatment estim sever asthma
patient liberti asthma ventur trial
liberti asthma ventur trial enrol patient oral glucocorticoid
treat asthma treat dupix placebo evert week
week trial show dupilumab treatment result lower rate
sever asthma exacerb activ arm vs placebo furthermor
activ arm show improv placebo
figur summari exacerb control chang
xolair provid use compar launch asthma
view xolair use compar initi dupix launch sever asthma
drug shown posit data sever asthma xolair record us sale
ex-u sale suggest meaning market
opportun dupix although xolair show clear notic
improv test patient age
patient older year age indic xolair improv lung
function overal form diseas wherea dupix suffici demonstr
fy asthma us marketdiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma mod/sever asthma laba mod/sever asthma fail laba mod/sever asthma fail uncontrol mod/sever asthma uncontrol mod/sever asthma dupilumab patients- per dose per per annual cost per revenu per us dupilumab demand uncontrol mod/sever asthma- discount rebates- build drawdown us dupilumab revenu uncontrol mod/sever asthma- figur dupix sever asthma eu market project
dupix growth atop dermat continu key focal point investor
next stage growth tie potenti adolesc approv late
approv would give access adolesc popul age
younger patient pediatr popul need wait full fda approv
age segment conduct phase studi pediatr age
mo year segment expect us approv pediatr atop dermat
sometim
fy marketdiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma mod/sever asthma laba mod/sever asthma fail laba mod/sever asthma fail uncontrol mod/sever asthma uncontrol mod/sever asthma dupilumab patients- per annual cost per revenu per inventori build drawdown discount rebateseu dupilumab revenu uncontrol mod/sever asthma- indicationagestatuspotenti launch yearadult atop year oldmarketedadolesc atop year oldphas atop year oldphas figur dupix atop dermat us market project
fy dermatitisu marketadult patient moder patient moder receiv elig treatment popul dupilumab treatment popul dupilumab pediatric- total patient durat therapi dose per per per annual cost per revenu per us dupilumab demand atop dermat us dupilumab demand atop dermat pediatr discount build drawdown us dupilumab revenu atop figur dupix atop dermat eu market project
clinic differenti cemiplimab key lung cancer given exist
approv competitor look detail call look key
direct progress free surviv benefit comparison regn
cemiplimab merck keytruda and/or bristol opdivo importantli merck
bristol alreadi approv inhibitor lung cancer merck hold
edg front-lin lung cancer
current perform trial cemiplimab non-smal cell lung cancer
nsclc one phase one phase one phase
pembrolizumab monotherapi studi conduct advanc
squamou non-squam nsclc express primari
endpoint studi progression-fre surviv month key
secondari endpoint overal surviv os overal respons rate orr
standard dose cemiplimab ipilimumab standard dose cemiplimab
studi conduct advanc metastat squamou non-squam
nsclc express primari endpoint studi overal
respons rate orr month key secondari endpoint overal
surviv os progress free surviv
fy dermatitiseu marketadult patient moder patient moder treatment popul treatment popul dupilumab pediatric- total patient durat therapi dose per per per annual cost per revenu per eu dupilumab demand atop dermat eu dupilumab demand atop dermat pediatr discount build drawdown eu dupilumab revenu atop regeneron pharmaceut
phase dose escal dose expans trial assess
safeti efficaci cemiplimab treatment-experienc
advanc metastat squamou non-squam nsclc primari endpoint
studi dose limit toxic safeti profil orr key secondari
endpoint os
order cemiplimab chanc compet highli competit nsclc
market incumb player name pembrolizumab nivolumab
especi front line indic pembrolizumab trial would
show strong data phase data data beat
pembrolizumab month base studi order gain
competit edg believ may provid long-term data
show long-term surviv benefit shot outcompet incumb
continu expect posit regulatori decis octob cemiplimab
approv treatment advanc cutan squamou cell carcinoma cscc
decemb pivot phase empower-cscc studi report orr
cscc patient time median durat respons yet
reach data cut-off howev accord regn/sni respons
on-going minimum follow-up data cut-off month view
posit given cscc limit treatment treatment standard
advanc stage cemiplimab receiv breakthrough therapi
design septemb expect high probabl approv
view approv cemiplimab cscc possibl strategi pivot
nsclc market parallel on-going trial nsclc data show
strong surviv benefit surviv benefit expect potenti off-label use
effect allow enter nsclc market prior full approv
aug oct oct ph studi osteoarthritisfda decis dose interv wet amddata ph year age atop dermatitisregulatoryfda decis bla advanc csccfda regulatori submiss pre-fil syring formulationdata ph polypsregulatori ex-u regulatori agenc decis applic adult atop dermat regulatori aug decis sbla use apheresisfda regulatori submiss npdr non-dm patientsregulatorysubmit cardiovascular risk reduct us eu treatment hyperlipidemia usregulatori sbla expand indic adolesc year age atop dermatitisfda decis uncontrol persist asthma figur valuat dcf
regeneron dcf valuat free yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount non-gaap epsp multipl regeneron pharmaceut
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- regeneron inc figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- regeneron incincom bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option sg collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand regeneron
